A Phase II/III Study Comparing Different Therapies for Metastatic Pancreatic Cancer

Share
Print

Full Title

Precision Promise Platform Trial for Metastatic Pancreatic Cancer (WIRB)

Purpose

Metastatic pancreatic cancer is very challenging to treat successfully. The purpose of this study is to compare novel treatments with standard treatment regimens for patients receiving initial or second-line therapy for metastatic pancreatic cancer.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic pancreatic cancer that has never been treated or has only been treated with one regimen of therapy.
  • At least 4 weeks must pass between the completion of prior therapy and receipt of the study treatment.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact the office of Dr. Anna Varghese at 646-888-4308.

Protocol

20-285

Phase

II/III

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators